Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crinecerfont in adults with classic congenital adrenal hyperplasia
2019-004873-17Phase 3Unknown
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in classic congenital adrenal hyperplasia comparing Crinecerfont + background glucocorticoid with Placebo + background glucocorticoid (2 arms). Primary endpoint: Percent change from baseline in glucocorticoid daily dose at Week 24. Status: unknown.
02
Drugs
crinecerfont
03
Conditions
classic congenital adrenal hyperplasia
Beyond the preview
Go deeper on 2019-004873-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004873-17.